Literature DB >> 32185152

Bladder Cancer in Iran: An Epidemiological Review.

Khadijeh Kalan Farmanfarma1, Neda Mahdavifar2, Hamid Salehiniya3.   

Abstract

PURPOSE: Bladder cancer is the sixth most common cancer in Iran. Information about the epidemiological situation of the disease and its risk factors is necessary for conducting a planning program to reduce the disease. This study is conducted with the aim of evaluating the epidemiological features of bladder cancer in Iran.
METHODS: This is a systematic review of the published articles in both Persian and English in international and national journals during the years 2000-2019 with key words of Iran and bladder cancer. Articles were selected from the national information database (SID, Magiran) and international databases (PubMed, Scopus, and Web of Science). Articles related to the epidemiological aspects of the disease, including incidence, prevalence, mortality, and risk factors, were evaluated.
RESULTS: The incidence rate of bladder cancer was about 1.6-115; cumulative survival rate was 0.95, mortality rate was 0.5-0.84 and its prevalence in the Iranian population was between 4.10% and 12.8%. The risk of developing malignancy in major risk factor groups, including smoking and opium, was 6.2 (2.04-18.7), increases in protein and animal fat consumption were about 5- and 19-times higher than in the general population, respectively. In terms of occupational exposure, bus and heavy truck drivers were 11.3 (1.3-92.05) more at risk than others.
CONCLUSION: Regarding the increasing trend of this disease, changes in lifestyle to reduce risk factors can be effective in decreasing the incidence and mortality rate of this malignancy.
© 2020 Kalan Farmanfarma et al.

Entities:  

Keywords:  Iran; bladder cancer; epidemiology; incidence; risk factor

Year:  2020        PMID: 32185152      PMCID: PMC7062394          DOI: 10.2147/RRU.S232417

Source DB:  PubMed          Journal:  Res Rep Urol        ISSN: 2253-2447


Introduction

Bladder cancer (BC) is the second most common type of urinary tract infection worldwide. Also, it is the fourth most common cancer in men and the ninth in women,1 with approximately 150,000 deaths in the world.1 The results of epidemiological studies show a wide range of genetic, anatomical, hormonal, social, and environmental factors in the development of disease.2 The incidence of this malignancy in the world is ~440,000 annually,3 the 5-year survival rates in the US and European countries were 76% and 68%, respectively, which is higher in high income countries than in other countries.4 The statistics indicate an increasing trend in prevalence of this cancer in Iran,5 with more than 70,000 new cases and 30,000 annually recorded deaths.6 Generally, 7.04% of cancers in Iran are related to bladder cancer.7 The most important risk factors associated with bladder cancer include tobacco, industrial exposures, and carcinogens such as aromatic amines, black carbon, prolonged use of arsenic or chlorine contaminated water, and family history.8 Information about the epidemiological situation of the disease and its risk factors is necessary for conducting a planning program to reduce the disease; also, there is no comprehensive conducted investigation in Iran that addresses various epidemiological aspects of the disease, therefore, the present study aims to examine the epidemiological aspects of bladder cancer in Iran.

Methods and Materials

This study systematically reviews articles carried out using national (SID, Magiran) and international databases (PubMed, Web of Science, Scopus) which were obtained from 2000–2019. The keywords included: “bladder cancer”, “bladder neoplasm”, “incidence”, “epidemiology”, “survival”, “mortality”, “prevalence”, “risk factor”, and “Iran”. The search was matched for each database. Original articles that examined epidemiological aspects of the disease, including incidence, mortality, prevalence, survival, and risk factors, were included in the study. Review articles, letters to the editor, and case reports were excluded.

Data Collection Process

Summaries and full text of the articles were independently reviewed by two authors and, if relevant for the purpose of this study, required information, including the author’s name, year of publication, place of study, sex of subjects, sample size, incidence, prevalence, mortality, and risk factors were extracted from each article and recorded in relevant tables. Finally, the information was presented qualitatively in the form of the tables.

Results

Description of Literature Search

A total of 723 articles were reviewed, 10 articles identified through other sources, 620 articles were duplicated, 274 articles were fully studied, 239 articles were unrelated, and finally 35 articles were included in the review (Figure 1).
Figure 1

Flowchart of the included studies in the systematic review.

Flowchart of the included studies in the systematic review.

Mortality

In Iran, the pattern of mortality rate reduction for bladder cancer is similar to that in high socioeconomic status countries. The mortality rate in the period of 1990–2015 decreased from 13.04 to 0.47 (Table 1).
Table 1

The Mortality Rate of Bladder Cancer in Iran

First Author (Year)Province (District)Type of StudySample Size(Sex)Age-Standardized Mortality Rate per 100,000 (ASMR)Death per 100,000 People
Babaei (2009)55Ardabil4,363MF0.5
Mazdak (2018)15IsfahanRetrospective study1,655MF (2011–2012)0.56
2012–20130.74
2013–20140.98
2014–20150.84
Pishgar (2018)9ALLof iranMF (1990)13.04 (10.04−16.95)
199510.94 (8.56–13.97)
20005.62 (4.46–7.08)
20052.5 (3.16–1.98)
20101.4 (1.78–1.1)
20150.47 (0.61–0.37)
Sadjadi (2005)77Golestan, Mazandaran, Kerman, Ardabil Tehran2,083MF1,059
Mahdavi (2015)78All of Iran105MF (2006)1.12
20071.09
20081.15
20091.1
20101.09
The Mortality Rate of Bladder Cancer in Iran Also, increasing in smoking among men and, at the same time, reducing the amount of cigarette consumption in women can justify a reduction in the mortality rate of bladder cancer. Meanwhile, behavioral, environmental, and metabolic changes should be considered as significant factors in reducing mortality.9 On the other hand, the efficacy and availability of diagnostic tools and therapeutic methods have been effective in reducing this malignancy. Nowadays, cystectomy is available for diagnosis and treatment in many parts of Iran,10,11 Table 1 shows the mortality of bladder cancer in Iran.

Incidence

Bladder cancer is the fifth most common cancer in Iranian men. Based on the findings of the previous studies, the standardized incidence rate in Iran was estimated to be between 1.6–115% . The highest standardized incidence of age was observed in Eastern Azerbaijan (17.6) and Kerman province (15.8). It should be noted that all previous findings in Iran reported that the incidence rate in men is more than that in women. This discrepancy is partly due to smoking habits differences among men and women, so that the incidence of malignancy in males is 1–4.8 in southern Iran and 1–7 in other regions of country. In addition to smoking, opium consumption and occupational exposure are important risk factors which increase the malignancy rate in men.6 It should be mentioned that the incidence rate in men and women varies from 1–6 to 1–2, and is higher in men than women, so that three quarters of new bladder cancer cases are observed in men,12 Table 2 shows the incidence of bladder cancer in Iran.
Table 2

Incidence Rate of Bladder Cancer in Iran

First Author (Year)Province (District)Type of StudySample SizeSexASR (Age-Standardized Incidence Rate)Incidence RateIncidence RatioMean±SD
Somi (2008)48East Azerbaijan4,922MaleFemale15.723.68
Akbari (2008)49Tehran8,147MaleFemale48.3
Rohani-Rasaf (2012)50TehranMaleSep-01 (6.3)Sep-02 (8.2)Sep-03 (14.2)Sep-04 (15.3)
Ahmadi (2018)51Chahrmahal and Bakhtiari2,918MF0.08
Shahesmaeili (2018)52KermanRetrospective study2,838Male24.70
Akbarzadeh (2012)53MazandaranCross-sectional310MF11.4
Aghajani (2016)54All of IranRetrospective study301,055MF11.252.49
Babaei (2009)55Ardabil4,363Mf13.1
Basiri (2014)56All of IranM (2003)M (2009)F (2003)F (2009)8.3512.591.492.44
Haghdoost (2015)57KermanCross-sectional3,052MF15.8
Rafiemanesh (2018)58North Khorasan2,165MF5.13
Rafiemanesh (2015)59Sistan and Baluchistan3,535MF (2004)1.24
Zahedi (2015)60Hamadan4,5923,175M (2004)M (2009)F (2004)F (2009)72.9132.048.2115.0
Sadjadi (2003)61Ardabil2,0721,309MaleFemale7.61.8
Sadjadi (2007)62Kerman3,2642,620MF6.71.6
Somi (2018)63East Azerbaijan6,655MF17.6
Salehiniya (2016)64Mazandran and GolstanCross- sectional6,17715,231MF15.416.77
Talaiezadeh (2013)65Khouzestan16,801MF10.694.07
Fararouei (2015)66Kohgiluyeh and Boyer-AhmadCohort660MF6.94
Keyghobadi (2015)67KermanCross-sectional5,793M (2004)200520062007200820097.739.719.4111.1713.2014.66
Mohagheghi (2009)68Tehran26,006MF13.33.8
Mazdak (2018)15IsfahanRetrospective study1,655MF (2011–2012)2012–2013)2013–2014)2014–20157.78.17.59.9
Masoompour (2016)69FarsM (1985–1989)M (1998–2002)M (2007–2010)F (1985–1989)F (1998–2002)F (2007–2010)7.506.815.602.001.903.93
Vakili (2014)70Yazd4,631MF7.5
Yavari (2008)71Tehran597MF12.8±61.9
Rahimi (2015)72TehranMF13.33.8
SemnanMF7.163
GolestanMF8.7
East AzerbaijanMF15.723.68
KhuzestanMF10.694.07
ShahroudMF9.393.16
Rafiemanesh (2016)73QOMCross-sectional3,029M (2004)200520062007200810.467.306.829.499.80
Rafiemanesh (2018)74All of IranCross-sectional23,291F (2003)20042005200620072008M (2003)200420052006200720082.122.492.862.993.323.788.359.911.311.6613.0314.42
Sadjadi (2005)62Golestan, Mazandaran, Kerman, Ardabil Tehran51,000M8.0
Enayatrad (2016)75All of Iran41,16932,898M (2004)2005200620072009F (2004)200520062007200911.311.713.014.412.62.92.93.33.83.3
Koohi (2015)76All of IranCross-sectional27,898MF (2003)2004200520062007200820094.694.704.714.714.634.484.49
Incidence Rate of Bladder Cancer in Iran

Survival

The average survival rate was ~24.2 months in the country. The survival time is related to only two variables of the place of living and the type of disease, given that the economic, social, and cultural structure of the developing countries is approaching advanced countries, it can be expected that the incidence of bladder cancer in Iranian women will increase in the future, since the 5-year survival rate of bladder cancer in women is 6 years less than that of men.13 Also, the cumulative survival rate in Iran was 0.95%, indicating that the survival rate of BC in Iranian patients is lower than in other areas. However, the effect of early diagnosis based on updated and effective methods in advanced countries should not be underestimated. In other words, this difference can be due to the existence of a decision-making process or lead time bias.14 Table 3 shows the survival rate of bladder cancer in Iran.
Table 3

The Survival Rate Associated with Bladder Cancer in Iran

First Author (Year)Province (District)Type of StudySexSample SizeAverage Survival RateSurvival RateCumulative Survival Rate
Ahmad (2003)13FarsCohort HistoricalMF7624.2 (18.3–30.1)
Mohammadbeigi (2011)14FarsRetrospective studyMF514One-year survival = 0.93 years = 0.75 years = 0.610 years = 0.20.9582
Vahedian-Ardakani (2018)47YazdRetrospective cohort studyMF340One-year survival = 913 years = 58 5 years = 51.4
The Survival Rate Associated with Bladder Cancer in Iran

Prevalence

Based on previous studies, the prevalence rate in this Iranian population was 33.2 per 100,000 people (Table 4). This rate in men is 4.8-times higher than that in women.15 The high prevalence of this malignancy can reflect the patterns of smoking and environmental carcinogens.16 Table 4 shows the prevalence of bladder cancer in Iran.
Table 4

The Prevalence of Bladder Cancer in Iran

First Author (Year)Province (District)Type of StudySample SizeSexPrevalence5 Year Prevalence
Nikfarjam (2014)79Mashhad4606MF4.10
Farahmand (2009)80Fars1440Mf(2002)2003200420052006173201207351314
Mazdak (2018)15IsfahanRetrospective study1655MF (2011–2015)33.2
Rahimi (2015)73Kermanshah7695MF12.8
Roshani (2016)81All of iranCross-sectional75,500MF9.6
Sadjadi (2005)77Golestan, Mazandaran, Kerman, Ardabil Tehran2083MF5970
The Prevalence of Bladder Cancer in Iran

Risk Factors

Smoking

Researchers report the high prevalence of smoking and opium consumption in the Iranian studied population.17 The chance of malignancy in Iran in smokers and opium users is 6.2 (2.04–18.7) and (1.8–7.8), being 8.3% times higher than those who only smoke (Table 5).
Table 5

Risk Factors Associated with Bladder Cancer in Iran

First Author (Year)Province (District)Type of StudySample SizeSexRisk FactorsORMean (SD; Min, Max)N (%)Median 95% Cl
Akbari (2015)18FarsCase-control198 (case)396 (control)MaleFemaleOpium3.9 (1.3–12.0)
Tobacco2.5 (1.3–4.8)
Alcohol2.9 (1.2–7.1)
Aminian (2014)36TehranCase-control160 (case)160 (control)MaleOccupational risk:1-bus and truck driving3.62 (1.04–12.89)
2-mechanics, working in refinery and Petrochemical, plastic2.71 (1.03–7.59)
3-Textile industry, Spinning, Hosiery2.23 (0.70–7.15)
4-House Keeping1.79 (0.90–3.67)
5-barberry, painting, Dye Manufacturing1.81 (0.69–4.83)
6-Shoe-making, production, seat cover, Embroidered bag, Repairing shoes1.12 (0.34–4.57)
7-welding, metal working, plumbing, turning2.46 (0.99–6.28)
8-driving1.57 (0.69–3.49)
9-office job1.15 (0.65–2.0)
10-carpentry, Mosaic work, cabinet making1.14 (0.27–4.07)
Ahmadi (2012)6MazandaranCross-sectional112MFOpium21.4
Tobacco45.5
History of cancer in family22.32
Khoubi (2013)34IsfahanCase-control300 (case)500 (control)Health professionals0.4 (0.04–4.80)
Petroleum and natural gas refining plant operators0.4 (0.18–1.50)
Clerks0.2 (0.11–2.49)
Domestic housekeepers5.9 (2.61–11.62)
Sales workers2.8 (0.81–2.01)
Shop assistants3.4 (0.91–7.21)
Skilled agricultural, forestry, and fishery workers6.0 (2.32–15.72)
Animal producers2.5 (0.70–9.04)
Building and related trades workers, excluding electricians3.8 (1.33–3.21)
Carpenters and joiners2.9 (0.77–12.13)
Painters and related workers1.8 (0.20–4.21)
Sheet and structural metal workers, molders and welders6.0 (2.84–14.08)
Food processing and related trades workers1.0 (0.22–3.52)
Car, van, and motorcycle drivers0.6 (0.07–5.60)
Heavy truck and bus drivers11.3 (1.32–92.50)
Mining and construction laborers1.2 (0.30–4.41)
Hosseini (2010)37TehranCase-control179 (case)179 (control)Opium4.60 (3.53–6.28)
Shakhssalim (2010)7Tehran, Khorasan, Khoozestan, Isfahan and East AzarbayjanCase-control692 (case)692 (control)MFOpium2.57 (1.55–4.26)
Hair dye1.99 (1.04–3.82)
Excessive analgesics use1.41 (1.02–1.94)
Sausage0.98 (0.70–1.34)
Ham1.24 (0.87–1.78)
Smoked fish0.78 (0.50–1.20)
Can0.80 (0.60–1.07)
Pickles0.93 (0.88–0.99)
Fruits0.97 (0.94–1.00)
Vegetables0.93 (0.89–0.97)
Farzaneh (2017)38YazdCase-control200 (case)200 (control)MFChronic or recurrent urinary5.92 (3.47–10.09)
History of chronic or recurrent urinary tract infection 2–3 years8.18 (2.18–30.69)
Analgesic use2.21 (1.30–3.75)
History of analgesic use ≥4 years11.81 (2.83–49.18)
Irradiation to pelvis1.69 (1.10–2.58)
History of irradiation to pelvis ≥4-times12.68 (3.51–45.76)
Kidney and bladder stones3.44 (2.06–5.75)
History of kidney and bladder stones ≥2 years8.07 (2.48–26.22)
History of diabetes2.15 (1.29–3.59)
History of other kidney diseases2.84 (1.8–4.46)
History of hypertension1.81 (1.08–3.02)
History of smoking2.87 (1.47–5.59)
Ghadimi (2015)39KurdistanCase–control152MFEx-smokerCurrent smoker2.549 (1.287–5.048)
Occupational risk:Driver1.714 (0.824−3.563)
Loom5.134 (0.593−44.47)
Carpenter3.039 (0.312–29.551)
Cleaner0.688 (0.376−1.258)
Painter1.342 (0.295−6.101)
Metal10.629 (1.343–84.093)
Construction worker0.814 (0.434–1.528)
Farmer0.819 (0.513–1.308)
Governmental employee1.128 (0.571−2.228)
BMI>251.041 (0.657−1.649)
Lotfi (2016)40YazdCase-control200 (case)200 (control)MFCigarette smoking3.16 (2.04–4.9)
Opium History3.01(1.73–5.23)
History of Hubble bubble and pipe2.63(1.48–4.64)
History of alcohol2.57 (1.04–6.35)
Oil Animal3.19 (1.64–6.21)
Fried food (per week)4.02 (2.32–6.95)
Red Meat >45.61 (3.02–10.41)
Mohseni (2004)41TehranCase-control185MFSmoking in the patients with high-grade tumors15.9 (6.7–36.9)
Motamed (2018)42FarsRetrospective756MFHookah consumption1.44 (1.01–2.1)
Hypertension1.36 (1.00–1.86)
Gender1.46 (0.99–2.15)
Mirsafa (2015)43TehranCase-control55 (case)110 (control)Animal fatFAT19.7612.92
Junk foods8.1
Organ meat5.47
Processed meat5.34
Sweets3.62
Jafari-Koshki (2017)44All of Iran17,792BMI>25 (2006)43.28±6.65
BMI>25 (2007)44.59±6.18
BMI>25 (2008)42.99±4.93
Cigarette (2006)11.94±1.92
Cigarette (2007)12.75±1.74
Cigarette (2008)11.64±1.94
Fruit (2006)1.13±0.24
Fruit (2007)1.32±0.27
Fruit (2008)1.42±0.40
Vegetables (2006)1.25±0.38
Vegetables (2007)1.38±0.42
Vegetables (2008)1.41±0.44
Low activity (2006)30.67±7.46
Low activity (2007)34.88±8.38
Low activity (2009)38.30±8.15
Mahaki (2011)45All of Iran62,037MFSmoking0.97 (0.43–2.11)
Socioeconomic0.92 (0.45–1.88)
Islami (2007)46TehranCase-control147 (case)39 (control)MFHPV virusei34.77.6
Risk Factors Associated with Bladder Cancer in Iran The risk associated with cigarette smoking is considered to be an important disposal factor for the incidence of bladder cancer of 50%.3 The use of opium in Iran over a hundred years is one of the most commonly used drugs. The number of addicts increases by 8% every year,18 also the largest growth is observed in northern and southern parts of Iran.19,20 As surveys show, opium consumption alone increases the chance of BC by 4.60-times (Table 5).

Gender and Age

The results reveal the differences in the incidence and survival rate among men and women, as these are higher in the male population.3 In a meta-analysis study, the lowest incidence rate in Iranian women is estimated at 0.4 per 100,000 people.5 Factors such as differences in access to healthcare, late diagnosis, occupational exposure, pattern of Cigarette smoking, and the presence of steroid hormone in the two sexes3 are the reasons for these discrepancies. Increasing age as a risk factor plays an important role in the incidence of BC. The results of studies in Iran showed that the mean age of patients with BC in Iran was 65.1, 61.9, and 55.5 years,6 so that 47% of new cases in Iran are over 65 years old.21

Lifestyle

High consumption of alcohol,22,23 low consumption of vegetables and fruits, and low levels of drinking water,24 also, consumption of water containing halo methane chloride,16,25 Schistosoma infection (9–25%), and occupational exposure to aromatic amines,26 Chronic bladder infection, history of diabetes, and metabolic syndrome27 are associated with the risk of developing BC. In this study, the association between alcohol consumption and malnutrition was reported to be around 9–57% (Table 1), the majority of studies in the world also refer to the relationship between alcohol and BC.28 Family history, as an important factor, Increases the risk of malignancy by 22.32% (Table 5), which itself indicates the role of genetics in the occurrence of this malignancy.29 It should be noted that obesity increases the risk of BC by 1.04-fold (Table 5). Since the relationship between obesity and type 2 diabetes is absolutely known, type 2 diabetes is associated with insulin resistance and serum IGF-1 levels, as in patients with BC, IGF-1 levels are significantly higher. On the other hand, diabetes is associated with an increased risk of bladder infection, which causes the higher incidence of BC.30 In the present study, diabetes also increased the risk of BC by 2.15-times (Table 5). Studies have shown that there is a relationship between diet and cancers.31 In this study, carbohydrates are associated with a 62% risk of BC incidence (Table 5). Meanwhile, taking green and yellow fruits and vegetables can have a protective effect on this disease. Fruits and vegetables reduce the risk due to the presence of alpha-beta-carotene, lycopene, lutein, and vitamins A, E, C, and F.32 In the investigated studies in Iran, the protective effect of fruits and vegetables was OR=0.97 (95% CI=0.94–1.00) and OR=0.93 (95% CI=0.99–0.99), respectively. In contrast, a high intake of meat and fat is associated with the risk of this malignancy.32 As a result, the consumption of animal protein increases the risk of infection in Iran by about 5, and with animal fat the risk is elevated by ~19-times (Table 5). In a study, 34.7% of the patients with BC were found to have an HPV virus, while in the control group the infection was 7.6%, indicating a relationship between the HPV virus and the incidence of BC (Table 5). In a meta-analysis, HPV outbreak worldwide was 16.88%,33 which is much lower than that reported in Iran. The difference can be due to genetic and environmental factors, sexual behavior, and ethnic and cultural differences in different parts of the world, including Iran.33

Occupational Exposure

In total, 20% of the causes of bladder cancer are due to occupational exposure.34 Based on previous research, the chance of developing BC among bus and heavy drivers is 11.3 (1.3–92.05), in farmers, fisheries, and forestry, it is 6.0 (2.32–15.72), and among metalworkers and welders it is 6.0 (2.84–14.08), these all being higher than others, such as carpenters, at 0.68 (0.35–1.25) (Table 5). On the other hand, evidence suggests that construction workers and those who deal with chemical substances are more likely to develop an invasive type of malignancy.35 The carcinogenic effects of occupational exposure are more due to the presence of benzidine, ortho-toluidine, 2- naphylamine, 4-aminobiphenyl, and 4,4ʹ-methylene-bis (2-chloroaniline) (MBOCA).16

Conclusion

The aim of this study was to determine the epidemiological aspects of bladder cancer in Iran. BC is the sixth most common cancer in the Iranian population, with a standardized incidence of 10.92 years for men and 2.80 for women. The incidence rate ranged from 1.6–115, the cumulative survival rate was 0.95, mortality ranged from 0.5–0.84, and the prevalence ranged from 4.10–12.8% . It seems that changes in Iranian lifestyle, as well as regular screening, can be effective in reducing the incidence and severity of this malignancy. Smoking and opium, consumption of red meat more than 4 times a week, animal fat, and occupational exposure such as bus and motor carriers are also considered risk factors for this cancer.
  61 in total

1.  Opium as a Risk Factor for Bladder Cancer: A Population-based Case-control Study in Iran.

Authors:  Morteza Akbari; Ahmad Naghibzadeh-Tahami; Narges Khanjani; Mohammad Reza Baneshi; Elham Kamali; Maryam Hesampour; Bahman Nazemzadegan; Ali-Akbar Haghdoost
Journal:  Arch Iran Med       Date:  2015-09       Impact factor: 1.354

2.  Obesity and risk of bladder cancer: a meta-analysis of cohort studies.

Authors:  Qi Qin; Xin Xu; Xiao Wang; Xiang-Yi Zheng
Journal:  Asian Pac J Cancer Prev       Date:  2013

3.  Cancer notification at a referral hospital of Kermanshah, Western Iran (2006-2009).

Authors:  Zohreh Rahimi; Razieh Kasraei; Farid Najafi; Maryam Tanhapoor; Hamed Abdi; Ziba Rahimi; Asad Vaisi-Raygani; Mozafar Aznab; Mahmoudreza Moradi
Journal:  Asian Pac J Cancer Prev       Date:  2015

4.  Prevalence of Types of Cancers in the Elderly Covered by Insurance of the Islamic Republic of Iran Broadcasting Company in 2015 - Comparison with Younger Groups.

Authors:  Zahra Roshani; Ahmad Ali Akbari Kamrani; Mohsen Shati; Robab Sahaf
Journal:  Asian Pac J Cancer Prev       Date:  2016

5.  Trends in Incidence of Common Cancers in Iran.

Authors:  Mostafa Enayatrad; Maryam Mirzaei; Hamid Salehiniya; Mohammad Reza Karimirad; Siavash Vaziri; Fiezollah Mansouri; Asieh Moudi
Journal:  Asian Pac J Cancer Prev       Date:  2016

Review 6.  Cancer stem cells as a therapeutic target in bladder cancer.

Authors:  Nazi Aghaalikhani; Nadereh Rashtchizadeh; Pejman Shadpour; Abdolamir Allameh; Marzieh Mahmoodi
Journal:  J Cell Physiol       Date:  2018-11-23       Impact factor: 6.384

7.  Predictive factors for prostatic involvement by transitional cell carcinoma of the bladder.

Authors:  Ali Tabibi; Nasser Simforoosh; Mahmoud Parvin; Hamidreza Abdi; Ahmad Javaherforooshzadeh; Farhat Farrokhi; Mohammad Hossein Soltani
Journal:  Urol J       Date:  2011       Impact factor: 1.510

8.  Cancer occurrence in Iran in 2002, an international perspective.

Authors:  Alireza Sadjadi; Mehdi Nouraie; Mohammad Ali Mohagheghi; Alireza Mousavi-Jarrahi; Reza Malekezadeh; Donald Maxwell Parkin
Journal:  Asian Pac J Cancer Prev       Date:  2005 Jul-Sep

9.  The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection.

Authors:  Martin C S Wong; Franklin D H Fung; Colette Leung; Wilson W L Cheung; William B Goggins; C F Ng
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

10.  Cancer incidence in the East Azerbaijan province of Iran in 2015-2016: results of a population-based cancer registry.

Authors:  Mohammad Hossein Somi; Roya Dolatkhah; Sepideh Sepahi; Mina Belalzadeh; Jabraeil Sharbafi; Leila Abdollahi; Azin Nahvijou; Saeed Nemati; Reza Malekzadeh; Kazem Zendehdel
Journal:  BMC Public Health       Date:  2018-11-19       Impact factor: 3.295

View more
  3 in total

1.  Linc00662 plays an oncogenic role in bladder cancer by sponging miR-199a-5p.

Authors:  Xin Ma; Yuanyi Wen; Yong Wang; Mingcheng Zhang; Lei Shi; Chen Wang; Zhishang Li
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

2.  Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis.

Authors:  Amir Hossein Aalami; Hossein Abdeahad; Mohammad Mesgari; Thozhukat Sathyapalan; Amirhossein Sahebkar
Journal:  Biomed Res Int       Date:  2021-04-27       Impact factor: 3.411

3.  Opium and Cigarette Smoking are Independently Associated with Bladder Cancer: The Findings of a Matched Case - Control Study.

Authors:  Zahra Abdolahinia; Hamid Pakmanesh; Moghaddameh Mirzaee; Azam Bazrafshan; Mehdi Shafiei Bafti; Armita Shahesmaeili
Journal:  Asian Pac J Cancer Prev       Date:  2021-10-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.